anti-SARS-CoV-2 convalescent plasma
/ Medical College of Wisconsin
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
August 25, 2022
A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection
(clinicaltrials.gov)
- P2 | N=131 | Completed | Sponsor: Medical College of Wisconsin | Active, not recruiting ➔ Completed
Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
January 08, 2021
A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection
(clinicaltrials.gov)
- P2; N=131; Active, not recruiting; Sponsor: Medical College of Wisconsin; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases
May 13, 2020
A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection
(clinicaltrials.gov)
- P2; N=131; Recruiting; Sponsor: Medical College of Wisconsin; Not yet recruiting ➔ Recruiting
Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease
1 to 3
Of
3
Go to page
1